💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ledipasvir

CHEMBL2374220 Phase 4 Onaylandı Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
889.0 g/mol
LogP
7.4
Phase
4

This NS5A inhibitor is used with sofosbuvir to treat chronic hepatitis C with high cure rates across multiple genotypes.

Moleküler Ağırlık

889,0000 g/mol

LogP

7,40

TPSA

175,00 Ų

Lipinski RO5

Başarısız

Terapötik Alanlar

Cardiovascular Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma HIV/AIDS Hepatitis C Heart Failure

Etki Mekanizması

Absorbs, reflects, or scatters ultraviolet radiation before it reaches the skin, protecting against UV-induced DNA damage and sunburn.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Absorbs, reflects, or scatters ultraviolet radiation before it reaches the skin, protecting against UV-induced DNA damage and sunburn.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C

                

                

                
                

                    
InChI

                    
InChI=1S/C49H54F2N8O6/c1-24(2)39(56-46(62)64-5)44(60)58-23-48(15-16-48)21-38(58)42-52-22-37(55-42)28-9-13-32-31-12-8-26(18-33(31)49(50,51)34(32)19-28)27-10-14-35-36(20-27)54-43(53-35)41-29-7-11-30(17-29)59(41)45(61)40(25(3)4)57-47(63)65-6/h8-10,12-14,18-20,22,24-25,29-30,38-41H,7,11,15-17,21,23H2,1-6H3,(H,52,55)(H,53,54)(H,56,62)(H,57,63)/t29-,30+,38-,39-,40-,41-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C49H54F2N8O6

                    

                    
                    

                        
HBD / HBA

                        
4 / 10

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
12

                    

                    
                    
                    

                        
Ağır Atomlar

                        
65

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
This NS5A inhibitor is used with sofosbuvir to treat chronic hepatitis C with high cure rates across multiple genotypes.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Absorbs, reflects, or scatters ultraviolet radiation before it reaches the skin, protecting against UV-induced DNA damage and sunburn.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Ledipasvir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2374220.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 67505836.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.